Skip to main content

Legend Biotech

Legend Biotech Corp is a global clinical-stage biopharmaceutical company developing cell therapies for oncology and hematologic malignancies. The company focuses on discovering and developing chimeric antigen receptor T-cell therapies, featuring its lead commercial product Carvykti for relapsed or refractory multiple myeloma. Principal revenues are generated through commercial sales of its cell therapy, collaborative development milestones, and licensing agreements with Janssen Biotech. Core end markets encompass specialized oncology medical centers, hematology treatment clinics, and academic research hospitals worldwide. Legend Biotech holds a pioneering market position in CAR-T cell therapy for hematologic cancers. The company is incorporated in the Cayman Islands, headquartered in Somerset, New Jersey, and its American Depositary Shares trade on the Nasdaq Global Select Market.

11 of the funds FundTelligence covers report a position in Legend Biotech.

Legal name
Legend Biotech Corp
Sector
Health Care
Country
United States
Funds holding it
11

Funds holding Legend Biotech

Showing the 8 largest of 11 funds holding it.

Loading...